$6.52
-0.34-4.96%
At close: Jul 10, 5:00 PM EST
$6.52
N/A
After Hours: Jul 10, 4:01 PM EST
Gyre Therapeutics Inc Stock Guidance
GYRENASDAQ
Gyre Therapeutics (GYRE) last issued guidance on May 7, 2026 for fiscal year 2026. The company guided revenue in the range of $100.50M - $111.00M for the period.
Compared to prior guidance, Gyre Therapeutics maintained its revenue forecast from a prior range of $100.50M - $111.00M.
Gyre Therapeutics has issued 3 guidance updates between March 17, 2025 and May 7, 2026. During this period, the company lowered its outlook 1 time, signaling management's revised expectations.
Latest Guidance Date
May 7, 2026
Guidance Period
Full Year 2026
Revenue Guidance Range
$100.50M - $111.00M
Gyre Therapeutics Guidance History
Review all historical guidance issued by Gyre Therapeutics, including EPS and revenue forecasts across quarterly and annual periods.
Loading calendar...
FAQ
What is the most recent guidance for Gyre Therapeutics (GYRE)?
The most recent guidance for Gyre Therapeutics (GYRE) was reported on May 7, 2026 for the fiscal year 2026. Gyre Therapeutics forecasted revenue between $100.50M and $111.00M for the period.
What revenue range did Gyre Therapeutics (GYRE) guide for?
Gyre Therapeutics (GYRE) guided revenue in the range of $100.50M to $111.00M for the fiscal year 2026.
Did Gyre Therapeutics (GYRE) raise or lower guidance?
Gyre Therapeutics (GYRE) maintained its revenue guidance from a prior range of $100.50M - $111.00M to $100.50M - $111.00M for the fiscal year 2026.
When did Gyre Therapeutics (GYRE) last issue guidance?
Gyre Therapeutics (GYRE) last issued guidance on May 7, 2026 for the fiscal year 2026.
